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CryoTEM  Cryo-transmission electron microscopy  
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DNPC   1,2-dinervonoyl-sn-glycero-3-phosphatidylcholine 
DOPC   1,2-dioleoyl-sn-glycero-3-phosphatidylcholine 
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MVA   Multivariate data analysis 
MPS   Mononuclear phagocyte system 
PC   Phosphatidylcholine  
PCS   Photon correlation spectroscopy 
PE   Phosphatidylethanolamine 
P.I   Polydispersity index 
PLS   Partial least squares regression analysis 
PP   Packing parameter  
SOPE 1-stearoyl-2-oleoyl-sn-glycero-3-phosphatidylethanolamine 
Tc   Gel-to-liquid crystalline phase transition temperature 






Liposome encapsulation of cytotoxic drugs favours drug delivery to tumours and improves the 
therapeutic-to-toxicity ratio of conventional chemotherapy. A novel approach to further enhance the 
availability of liposomal drugs to tumour cells is to combine ultrasound (US) with US sensitive 
(sonosensitive) liposomes. US treatment of tumour tissue induces local drug release from the liposome 
carrier followed by increased drug uptake into tumour cells. The liposomes, however, should display 
properties that both favour high sonosensitivity and drug retention in the blood circulation prior to 
reaching the tumour tissue. 
In the present study novel sonosensitive doxorubicin (DXR)-containing liposomes were 
developed. Inclusion of non-bilayer forming lipids in liposomal membranes was shown to 
significantly improve sonosensitivity. Two classes of liposomes based on 
distearoylphosphatidylethanolamine (DSPE) and dioleoylphosphatidylethanolamine (DOPE), 
respectively, were investigated. DOPE, displaying a more pronounced inverted cone shaped geometry 
than DSPE, was the most potent modulator of sonosensitivity. Inclusion of 25 mol% DOPE                  
in liposome membranes comprising distearoylphosphatidylcholine, PEGylated 
phosphatidylethanolamine and cholesterol resulted in an up to 7-fold increased US-mediated DXR 
release in vitro. The postulated mechanism of drug release is disruption of PE-based liposomes on US 
exposure. We suggest that US energy triggers perturbations and/or lamellar to reverse hexagonal 
phase transitions in liposomal membranes comprising non-bilayer forming lipids, leading to drug 
release. 
Selected liposome formulations were investigated in terms of blood pharmacokinetics in mice. 
Membrane composition was important for retaining DXR in blood circulation. Low levels of DOPE 
(25-32 mol%) were required to obtain long blood circulation times of DXR. Optimized DOPE-
containing liposomes featured both sufficient blood circulation time and high in vitro sonosensitivity.  
A significant tumour growth regression effect was demonstrated in tumour-bearing mice 
receiving prototype liposomes and US. The data support the concept that an US activated liposomal 





Liposomes are spherical vesicles composed of an aqueous core surrounded by a membrane that 
is usually composed of phospholipids 1. Phospholipids are amphiphiles, which form colloid 
dispersions in water. The hydrophilic part of the molecule tends to be in contact with the water, 
whilst the hydrophobic acyl chains are shielded against water in the interior of the membrane. 
The vesicles formed may consist of one or more concentric bilayers (lamellae), and have a size 
range from nanometers to micrometers (For a review see 2). The composition of the aqueous 
core as well as a lipid membrane gives the liposome the ability to incorporate both hydrophilic 
and hydrophobic drugs. Hence, liposomes can be used as a drug delivery system of cytotoxic 
drugs in cancer treatment. To understand the behaviour of liposomes for drug delivery, some 
general features of phospholipids and phase behaviour are presented in the following section.  
 
Figure. 1.1 A schematic illustration of a liposome containing drug in the aqueous core. 
Epitarget! 
 
1.2 Phospholipids and aggregate structure 
Phospholipids are the major components of biological membranes. The phospholipid molecule 
consists of two fatty acids, which are connected to a glycerol backbone with a polar phosphate 
headgroup via ester bonds  (Figure 1.2).  
Phospholipids are classified according to the type of polar headgroup, acyl chain length 
and degree of saturation. Phosphatidylcholines (PCs) are the most commonly used lipids in 
liposome formulations. PCs can be derived synthetically or from natural sources such as egg 
and soy. Phosphatidylethanolamines (PEs) are another group of phospholipids where PE 
substitutes the –N+(CH3)3 polar headgroup with –N+(H3) (For a review see 2). Figure 1.2 shows 
the general structure of a phospholipid and the structure of distearoylphosphatidylcholine 
(DSPC), distearoylphosphatidylethanolamine (DSPE) and dioleoylphosphatidylethanolamine 




DOPE: R1=R2= C18:1, R3= -CH2CH2
!NH3 
DSPE: R1=R2= C18:0, R3= -CH2CH2
!NH3 
DSPC: R1=R2= C18:0, R3= -CH2CH2
!N(CH3)3 
 
Figure 1.2 General structure of a phospholipid molecule and the structure of DOPE, DSPE and 
DSPC. 
 
The type of structure formed when phospholipids are dispersed in water is not only 
determined by the amphiphilic characteristics of the lipid, but also its shape, defined by the 
packing parameter (PP) 3. The PP is defined as the ratio of the geometrical area of the 
hydrophobic to polar regions of the amphiphile, PP=v/l x a, where v is the volume of the 
molecule, a is the area of the polar head group, and l is the length of the hydrocarbon chains 3 
(Figure 1.3). 
 
Figure 1.3. Geometrical shape and packing parameters (PP) of lipids and the structures they 
form. Epitarget! 
 
Lipids like DSPC, where the ratio of hydrophobic tails to polar headgroup equals 1, 
have a natural tendency to form bilayers 3. Lipids with a PP <1/3, e.g. fatty acids and lysolipids, 
form micelles 3. In the case of non-bilayer forming lipids, like DOPE, the headgroup is small 
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compared to the bulky hydrocarbon chains (PP>1), which does not enable the lipid alone to 
form liposome bilayers at physiological pH. Instead DOPE forms reversed structures where the 
bulky hydrophobic part of the lipid imposes an orientation towards the aqueous phase 3. At 
pH>8, the polar group deprotonates, increases its size due to increased hydration, and liposomes 
may be formed. Bilayers may also be formed when PEs are mixed with bilayer stabilizing lipids 
like DSPC or polyethylene glycol (PEG) grafted lipids, resulting in a net curvature of a bilayer 
3,4.   
The choice of lipid composition will to a great extent define the stability of the 
liposomes, including the gel-to-liquid crystalline phase transition temperature (Tc) and 
membrane permeability. Tc is a given temperature at which the hydrocarbon chains in the 
membrane melt from a tightly ordered gel phase to a liquid-crystal phase, which is more 
permeable to ions and molecules (For a review see 2). At physiological temperature, liposomes 
composed of saturated phospholipids, which have a high Tc, will be more rigid than liposomes 
composed of unsaturated phospholipids, which renders the former less prone to drug leakage. 
Cholesterol is often used in liposomes to induce mechanical stability by tightening the 
membrane and reducing leakage of entrapped drug 5-7. Liposomes composed of long saturated 
PCs, such as DSPC, and cholesterol are the most studied liposome formulations within drug 
delivery. 
 
1.3 Liposomes in cancer treatment 
The main rationale for developing liposomes as drug delivery systems for chemotherapeutic 
drugs is the unspecific distribution of most antineoplastic drugs in the body, giving a low 
therapeutic-to-toxic ratio. Liposome incorporation of drugs significantly alters the 
pharmacokinetics and biodistribution of the drugs 8. Small liposomes, slightly below 100 nm in 
diameter, are able to circulate in blood reaching specific targets such as solid tumors 9-12. The 
accumulation of liposomes into solid tumours is possible due to dissimilarities between healthy 
and cancerous tissues. Tumours are generally dependent on an increased blood supply compared 
to normal tissue because of the high turnover of neoplastic cells. Furthermore, the endothelium 
is often more permeable than normal endothelial linings because of larger gaps 12,13. This gives 
nanosized drug carriers, like liposomes, the ability to diffuse into the interstitium of solid 
tumours 9,12-14. At the same time the liposomes are retained in the tumour tissue due to reduced 
lymphatic drainage 13. This increased accumulation is often referred to as the enhanced 
permeability and retention effect 12,13.  
The extent of liposome accumulation in tumour tissue is largely determined by the 
blood circulation time of the liposome carrier, where long circulation times of the liposomal 
drug provide greater tumour delivery 9,14. Extended blood circulation time of liposomes is 
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achieved by reducing the liposome size, preferably slightly below 100 nm in diameter, and by 
coating the liposomes with the hydrophilic polymer polyethylene glycol (PEG) 15. The 
hydrophilic bulky PEG moiety prevents or minimizes interactions between plasma opsonins and 
the liposome surface due to steric hindrance, thereby retarding recognition of the liposomes by 
the mononuclear phagocyte system (MPS) 16.  
 
1.4 Doxorubicin-containing liposomes 
For chemotherapeutic drugs to be suitable for drug delivery by means of liposomes the drugs 
must be able to be efficiently loaded into the liposome where it is retained en route to the 
tumour. The anthracycline doxorubicin (DXR) is a suitable chemotherapeutic agent for 
liposomal drug delivery, mainly due to the efficient remote loading technique, resulting in a 
high drug-to-lipid ratio 17. Most of the drug forms a crystalline-like precipitate in the liposomal 
aqueous core, lacking osmotic effects and thus contributing to the stability of the entrapment 17. 
Encapsulation of DXR into PEGylated liposomes results in extended circulation time and a 
reduced volume of distribution compared to free DXR, thereby promoting tumour uptake 18. 
PEGylated liposomal DXR is one of about 10 marketed liposome products, known as Doxil! in 
the USA and Caelyx! in Europe 18. The formulation is approved for treatment of AIDS related 
kaposi sarcoma, metastatic breast cancer and recurrent ovarian cancer 18. 
 
1.5 Triggered release  
An inherent contradiction to the enhanced tumour delivery of liposomes exhibiting high drug 
retention is that drug availability to tumour cells may be severely limited. After the liposomes 
have accumulated in the tumour interstitial space, the encapsulated drug must be released before 
it can be sufficiently taken up by the surrounding neoplastic cells. A fast drug release from 
liposomes is especially important for fast growing tumours, where cells divide more rapidly 
than the liposomes can distribute to tumours and release their contents 8. In the case of long 
circulating PEGylated liposomal DXR, the drug has shown to release slowly from the liposomes 
19,20. Thus, triggered release of the liposomal drug within the tumour area might lead to a 
substantial increase in drug availability and thus improve the therapeutic efficacy.  
Throughout the last decades various approaches have been attempted to enhance local 
drug delivery to tumours by triggering drug release from liposomes, including hyperthermia, 
enzymatic and pH strategies 21-25. The idea is that an environmental change will trigger liposome 
membranes to structural rearrangements that induce leakage of the encapsulated drug. Thermo-
sensitive liposomes (TSL) combined with high intensity frequency ultrasound (HIFU), 
microwave or radiofrequency treatment are examples where localized hyperthermia in the 
tumour tissue induces drug leakage from TSL as a result of increased membrane permeability 
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above 37°C 26,27. TSL have typically Tc in the range of 40-45 °C, which facilitates drug leakage 
at these temperatures and above 28. A general limitation for thermo-sensitive formulations, 
however, has been premature leakage of the entrapped drug in blood circulation prior to 
reaching the tumour tissue, which in turn may limit the benefit of the strategy.  
Recently, non-thermal ultrasound (US) has been suggested as an alternative non-
invasive approach to enhance drug delivery of chemotherapeutics to solid tumours via 
liposomes 29,30.  
 
1.6 Ultrasound-mediated drug delivery  
US is in clinical use for diagnostic imaging and therapeutic purposes. High intensity frequency 
ultrasound (HIFU) is used to thermally ablate solid tumours such as uterine fibroids 31 and 
prostate cancer 32. In recent years the potential of using US to enhance delivery of 
chemotherapeutics to solid tumours via drug carriers has been investigated 29,30,33,34. Acoustic 
cavitation generated by US has shown to increase permeability of phospholipidmembranes, thus 
inducing both drug release from liposomes and enhancing drug uptake into cancer cells. For a 
recent review see Frenkel 30.    
Acoustic cavitation may be defined as the growth, oscillation and collapse of small, 
stabilized gas bubbles under the influence of the varying pressure field of a sound wave in a 
fluid medium 33. There are two distinct types of acoustic cavitation; stable, and inertial 
cavitation. Stable cavitation persists for repeatable acoustic cycles, where the bubble size is 
fairly stable. At increased US intensities, inertial cavitation may occur, where the bubbles grow 
faster, increase in size where they oscillate unstably, and finally collapse 33. Inertial cavitation is 
considered to be the primary ultrasound cause for increasing cell-permeability and drug release 
from liposomes 30. The underlying mechanism, although not fully established, is related to the 
collapse of microbubbles near the surface of the cells or liposome surface, which induce pores 
in the phospholipid membrane 33. Hence, US focused to tumours upon accumulation of drug-
containing liposomes may both induce release of the drug load from the liposome carrier and 
increase uptake into tumour cells, thus enhancing local drug delivery (Figure 1.4). The US 




Figure 1.4 Ultrasound-mediated drug delivery to solid tumours by means of sonosensitive 
liposomes. Epitarget ! 
 
1.7 Sonosensitive liposomes 
US sensitive (sonosensitive liposomes) are liposomal drug carriers designed for releasing their 
drug load on exposure to US (Figure 1.5). Preclinical research in designing sonosensitive drug-
containing vesicles is ongoing. Several studies have shown that gas-containing liposomes are 
highly sonosensitive 35-37. However, gas-filled liposomes are typically micron-sized and thus too 
large to allow effective extravasation into tumour tissue 34. Another limitation of gas-filled 
liposomes has been the rapid dissolution of the entrapped gas in the blood circulation with 
consequent loss of sonosensitivity.34  
Although it has appeared to be a general assumption that gas is required to make drug 
carriers responsive to non-thermal US, a few studies have demonstrated that membrane 
composition can influence on liposome sonosensitivity 38-40. Lin and Thomas found that 
inclusion of PEGylated distearoylphosphatidylethanolamines in liposome bilayers enhanced 
liposomal release of a drug marker upon exposure to low frequency US (LFUS) 38.  
Recently, we have further explored the influence of liposome membrane composition 
on sonosensitivity with the intention of developing efficacious sonosensitive liposomes for US-
mediated drug delivery. The formulation and characterization of the novel sonosensitive 




Figure 1.5 Sonosensitive liposomes release their drug load on exposure to ultrasound. 
Epitarget ! 
 
2. AIM OF THESIS 
 
The overall aim was to develop novel sonosensitive liposomes for US-mediated drug delivery to 
solid tumours.  
 Several specific aims were set for the liposome formulation work: 
- Liposomes should allow for high and stable drug entrapment.  
- Liposomes should efficiently release their drug load on US exposure.  
- The liposomes should have good stability, both on the shelf and in serum. 
- The liposomes should display long blood circulation time in vivo (1-2 days), enabling 
sufficient tumour accumulation. Liposome size should therefore be slightly below 100 
nm in diameter.  
 
The first section of the thesis includes formulation design of novel sonosensitive liposomes 
where the influence of liposome membrane composition on sonosensitivity is investigated 
(papers I, III, IV, V). Further, studies investigating potential mechanisms of drug release from 
liposomes on exposure to US are discussed (paper III). Thereafter follows evaluation of in vitro 
stability of liposomes, as well as in vivo blood circulation time of selected formulations in non-
tumoured mice (paper V). In the last section a first proof of principle study of prototype 
liposomes in tumour-bearing mice is described (paper II). 
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3. MATERIALS AND METHODS 
 
3.1 Materials 
All phospholipids were purchased from Genzyme Pharmaceuticals, Liestal, Switzerland. 
Cholesterol, organic solvents, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 
ammonium sulfate, calcein, sodium azide, Triton X-100! solution and sucrose were obtained 
from Sigma Aldrich, Oslo, Norway. Serum of fetal bovine origin was obtained from Autonorm, 
Sero, Billingstad, Norway. Doxorubicin hydrochloride (DXR) was purchased from Nycomed, 
Asker, Norway. Caelyx! was obtained from the pharmacy at the Norwegian Radium Hospital, 
Oslo, Norway (European distributor Schering-Plough). For anesthesia of mice, a mixture of 2.4 
mg/ml tiletamine and 2.4 mg/ml zolazepam (Zoletil®vet; Virbac Laboratories, Carros, France), 
3.8 mg/l xylazine (Narcoxyl® vet; Roche, Basel, Switzerland) and 0.1 mg/ml butorphanol 
(Torbugesic®; Fort Dodge Laboratories, Fort Dodge, IA) was prepared and used. Physiological 
saline was supplied by Fresenius Kabi, Halden, Norway.  
 
3.2 Methods 
3.2.1 Liposome preparation and characterization  
DSPE and DOPE-based liposomes of different membrane compositions were prepared by the 
thin-film hydration method and sequential extrusion technique (For reviews of methods see 41,42. 
(See papers I-V for details regarding lipid membrane compositions). In brief, lipids were 
dissolved in chloroform/methanol (9/1 v/v) at 60 °C and rotary evaporated to dryness under 
vacuum. For preparation of calcein-containing liposomes, the dry lipid films were hydrated with 
isotonic sucrose solution containing 10 mM HEPES (pH 7.4) and 50 mM calcein to result in a 
lipid concentration of 16 mg/ml. For preparation of DXR-containing liposomes 300 mM 
ammonium sulfate solution was used for hydration, resulting in a lipid concentration of 20 
mg/ml. The hydrated liposomes were submitted to three freeze–thaw cycles in a dry 
ice/acetone/methanol mixture and water, respectively (For a review of the method see 41). The 
liposomes were reduced in size by stepwise extrusion (Lipex extruder, Biomembrane Inc., 
Vancouver B.C., Canada) through polycarbonate filters with pore sizes of 800, 400, 200, 100 
and 80 nm (Nuclepore, West Chester, PA, USA). The lipid hydration, liposome extrusion and 
thawing process  were performed at temperatures above the nominal Tc of the 
phospholipid blends. 
 Untrapped calcein was removed by dialysis against an isotonic sucrose solution 
containing 10 mM HEPES and 0.01 w/v% sodium azide by placing disposable dialysis bags 
(MW cut off 100,000 D) (Spectra/Por!, Float-A-Lyzer!, Spectrum Laboratories, Inc., Rancho 
Dominguez, CA, USA) containing the liposome dispersion in a magnetically stirred dialysis 
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solution for approximately 3 days (volume ratio liposome dispersion:dialysis solution, 1:100 
v/v) with intermediate exchanges of the dialysis solution (For a review of the method see 41).  
 
Liposome entrapment of doxorubicin 
DXR was remote loaded into liposomes using an ammonium sulfate transmembrane gradient as 
previously described 17, resulting in a concentration of 1 mg/ml DXR and 16 mg/ml lipids. The 
gradient was obtained by dialysis of DOPE-based liposomes against isotonic sucrose solution 
containing 10 mM HEPES (pH 7.4) (herein referred to as sucrose/HEPES solution). Non-
buffered isotonic sucrose solution was used for dialysis of DSPE-based liposomes.  
 The dialysis was performed for approximately 48 h, with  intermediate exchanges of the 
dialysis solutions as described above. To provide optimal loading efficiency, the DOPE- and 
DSPE-based liposome dispersions were, after DXR addition, further incubated under stirring for 
60 min at 35 !C and for 30 min at 75 !C, respectively. Any remaining non-encapsulated DXR 
was removed by liposome dialysis against sucrose/HEPES solution containing 0.01w/v% 
sodium azide, as described above.  
 
Determination of entrapment efficiency of DXR 
To estimate the percentage of DXR entrapment, aliquots of both the dialyzed and the non-
dialyzed liposome sample were diluted 1:500 (v/v) with sucrose/HEPES solution and dissolved 
with Triton X-100 surfactant solution in a 50:1 (v/v) ratio. The entrapment efficiency (%) was 
calculated according to:  
 
Equation 1: (Fen " Fb )/ (Ftot"Fb)#100%  
 
where Fen is the fluorescence intensity in the dialyzed and surfactant treated liposome sample, Fb 
is the initial background signal of the dispersion medium (sucrose/HEPES solution) and Ftot is 
the fluorescence intensity in the non-dialyzed and surfactant treated liposome sample.  
 Fluorescence intensity measurements were performed using a fluorescence spectrometer 
from Ocean Optics (model QE65000, Duiven, Netherlands). The excitation and emission 
wavelength of DXR were 488 and 595 nm, respectively.  
 
Liposome size measurements 
The mean intensity-weighted hydrodynamic liposome diameter was determined by photon 
correlation spectroscopy (PCS). Prior to measurements the liposome dispersions were diluted 
1:200 (v/v) with 0.22 µm filtered sucrose/HEPES solution.  The measurements were performed 
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at 23 ºC and at a scattering angle of 90° (Nanosizer, Malvern Instruments, Malvern, UK). The 
width of the particle size distribution was expressed by the polydispersity index (P.I).  
 
3.2.2 Low frequency ultrasound experiments 
Low frequency US release measurements were conducted using a 40 kHz US transducer (VC 
750, Sonic and Materials, Inc, Newtown, CT, USA) with a 19 mm diameter nonfocused probe 
connected to a custom-built sample chamber as previously described by Huang and MacDonald 
37 (Figure 3.1). The temperature in the sample chamber was kept constant at 25 ºC by a water 
circulator system. The liposome dispersions were diluted in a 1:500 (v/v) ratio with 
sucrose/HEPES solution or sucrose/HEPES solution containing 20% (v/v) serum, respectively, 
just prior to the US experiments. The diluted liposome dispersions were exposed to 40 kHz US 
at a nominal intensity of 12 W/cm2 in a continuous mode (100 % duty cycle) up to 6 min. 
Acoustic pressure measurements conducted with a Bruel and Kjaer hydrophone (Type 8103, 
Denmark) in the sample chamber gave 240 kPa (pk–pk). The temperature in the liposome 
samples never exceeded 30 °C during the US experiments, excluding the possibility of direct 
thermal effect of US on liposomal drug release.  
The DXR or calcein release could be monitored due to the relief of fluorescence self-
quenching in the external liposomal phase, and concomitant increase in fluorescence intensity 
43. Fluorescence measurements were carried out as described above. Release was calcluated 
using the following equation:  
 
Equation 2:  % Drug release = (Ft – F0)/ (Fmax-F0)*100 
 
Where Ft is the fluorescence intensity in the liposome sample after a given duration (t) of US, F0 
is the initial background fluorescence of the diluted liposome sample prior to US, and Fmax is the 
fluorescence intensity after liposome solubilisation with surfactant (Triton X-100!). The 






Figure 3.1 Picture of the 40 kHz US set-up. 
 
3.2.3 High frequency ultrasound experiments 
High frequency US release measurements were performed using a custom built US set-up 
providing a standardized US dosimetry, as described by Somaglino et al. 44 (Figure 3.2). The 
US experiments were conducted in Dr. Cyril Lafon’s laboratory at INSERM U556, Lyon, 
France. In brief, a 1.13 MHz focused US transducer was used to generate cavitation. A needle 
hydrophone was inserted into the liposome sample vial and placed into degassed water in front 
of the transducer to detect cavitation. The chosen US dosimetry parameters were: 25% duty 
cycle, 200 Hz pulse repetition frequency, spatial peak-temporal average intensity (Ispta) = 5500 
W/cm2. The liposome dispersions were diluted in a 1:500 (v/v) ratio with sucrose/HEPES 
solution just prior to the US experiments. US-mediated release of liposomal calcein and DXR 
was calculated according to Equation 2. The excitation and emission wavelength for the 





Figure 3.2 Schematic drawing of the 1.13 MHz US setup. The drawing is adapted from 
Somaglino et al., with permission from Elsevier publisher.  
 
3.2.4 Cryo-TEM analysis 
Cryo-TEM analysis was performed in collaboration with Prof. Rolf Schubert and Sabine 
Barnert at the Dept. of Pharmaceutical Technology, University of Freiburg, Germany. US-
treated liposome dispersions for Cryo-transmission electron microscopy (CryoTEM) analysis 
were diluted 1:10 v/v with 0.22 µm filtered sucrose/HEPES solution prior to US. The non-
treated liposome dispersions were not diluted prior to analysis.  
Cryo-TEM investigations were performed according to methods described by Rank et 
al. 45, using a LEO 912 OMEGA electron microscope (Zeiss, Oberkochen, Germany) operating 
at 120 kV. A drop of the sample was placed onto a copper grid (Quantifoil® S7/2 Cu 400 mesh, 
holey carbon films Quantifoil Micro Tools GmbH, Jena, Germany). Excess solution was 
removed by a filter paper, leaving a thin liquid film with a thickness of 100-500 nm. The sample 
was then immediately shock-frozen by plunging it into liquid ethane. The vitrified sample was 
stored at 90 K in liquid nitrogen until it was loaded into a cryogenic sample holder (D626, 
Gatan Inc, Pleasanton, USA). The specimens were examined at -174 °C. Digital images with a 
magnification of 6300x or 12500x were recorded with a slow-scan CCD camera system 
(Proscan HSC 2). Minimal under-focus of the microscope objective lens was provided to obtain 





3.2.5 Effect of US on chemical integrity of DXR, cholesterol and phospholipids  
Assay and purity of DXR, and assay of cholesterol, DOPE, DSPE and DSPC before and after 
exposure of liposomes to 6 min 40 kHz US and 1.13 MHz US (cavitation dose of 200, 25% duty 
cycle, 200 Hz pulse repetition frequency, Ispta = 5500 W/cm2), respectively, was analyzed by 
high performance liquid chromatography (HPLC). Vitas AS, Oslo, performed the analyses.  
Five-point calibration curves were made from analysis of calibrators with known 
concentrations of DXR, cholesterol and phospholipids, respectively. For determination of DXR 
25 !L of the liposome suspensions was extracted with 650 !l 2-propanol and water. After 
thorough sonication and mixing (5 + 15 min) and centrifugation (5 min, 4000 g at 10 °C), an 
aliquot of 3 !L was injected from the supernatant into the HPLC system. HPLC analysis was 
performed with a HP 1200 liquid chromatograph (Agilent Technologies, Palo Alta, CA, USA) 
with a HP1200 diode array detector (DAD) operated at 480 nm. DXR was separated from the 
matrix on a 4.6 mm x 50 mm reversed phase C18 column. The column temperature was 50 °C.  
Cholesterol and phospholipids were determined by LC-UV and LC-MS, respectively. 
20 !L of the liposome samples was extracted with 5000 !l 2-propanol, followed by sonication 
and mixing (5 + 5 min).  
For quantification of cholesterol an aliquot of 20 !L was injected into the HPLC 
system. The HP1200 DAD operated at 204 nm. Cholesterol was separated from the matrix on a 
4.6 mm x 150 mm reversed phase C18 column. The column temperature was 50 °C.  
For quantification of phospholipids, an aliquot of 2 !L of the liposome suspensions was 
injected into the HPLC-Mass Spectrometry (HPLC-MS) system. HPLC-MS was performed 
with a HP 1100 liquid chromatograph (Agilent Technologies, Palo Alta, CA, USA) with a HP 
LC/MSD SL mass spectrometer operated in single ion monitoring mode. Internal standards 
were used to adjust for sample injection volume and ion suppression. DSPC, DOPE and DSPE 
were separated from the matrix on a 4.6 mm x 50 mm reversed phase polymer column. The 
column temperature was 60 °C.  
 
3.2.6 In vitro liposome stability 
Storage stability 
Physicochemical stability of liposomes was followed up to 6 months storage at 5 °C. The testing 
included re-determination of mean liposome size and size distribution, sonosensitivity, retention 
of encapsulated DXR, and chemical integrity of DXR, DOPE, DSPC, DSPE and cholesterol. 




Stability in serum 
Liposome stability in serum was studied in vitro using a serum-induced leakage assay 28,47. 
Liposome dispersions, diluted 1:125 v/v with sucrose/HEPES solution and 20% serum, were 
incubated at 37 °C up to 6 or 24 h. Time-dependent leakage of liposomal DXR or calcein was 
quantified by fluorescence measurements of serum samples further diluted 1:4 v/v with the 
sucrose/HEPES solution, according to Equation 2. 
 
3.2.7 Animal studies 
Animal studies were performed in collaboration with Eirik Hagtvet at the Department of 
Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Norway. All animal 
studies were performed according to protocols approved by the National Animal Research 
Authority and in compliance with the European Convention for the Protection of Vertebrates 
Used for Scientific Purposes.  
 Male athymic nude Balb/c mice were provided by the Department of Comparative 
Medicine (animal facility), the Norwegian Radium Hospital. The mice were housed in 
transparent boxes with bedding material, fed ad libitum and kept under specific pathogen-free 
conditions. The temperature and relative humidity were kept constant at 20-21°C and 60%, 
respectively. At the end of the experiments all animals were euthanized by cervical dislocation. 
 
Pharmacokinetic studies in non-tumoured mice 
Non-tumoured mice were administered with 7 mg liposomal DXR/kg body weight. 
Standard liposomal DXR was administered at 14 mg/kg due to the doubled drug-to-lipid ratio of 
the formulation (1:8 drug/lipid) vs. DOPE-based liposomes  (1:16 drug/lipid). Thus, the dosing 
was based on an identical lipid dose for all investigated liposome formulations, as the lipid dose 
(i.e. liposome dose) is generally known as a key factor influencing blood pharmacokinetics 8.  
 The liposomes were injected intravenously (i.v.) into the tail vein under anaesthesia 
induced by subcutaneous administration. Animals were sacrificed in groups of three at different 
time points post-injection (0.5, 1, 3, 8 12, 24 and 48 h). Blood samples were obtained by cardiac 
puncture using heparinized syringes and stored in heparinized tubes. All blood samples were 
kept on ice bath until storage at -80 °C. Extraction of DXR from blood was performed 
according to methods described by Gabizon et al. 48. The extracted DXR was quantified by 
fluorescence measurements as previously described.  
 
Therapy study in tumoured mice 
CWR22 prostate adenocarcinoma, initially obtained from patients during surgery, was serially 
transplanted between mice. In brief, by blunt dissection through a skin incision a tumour 
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fragment (~2x2x2 mm) was subcutaneously implanted into the flank of 4-5 weeks old mice. The 
skin incision was sealed with topical skin adhesive. Approximately three weeks later a tumour 
xenograft of 5-7 mm in diameter had developed.  
The animals were randomly allocated into 4 groups (n=8) according to different 
treatment regimes. A dose of 3.5 mg/kg liposomal DXR was given i.v. to anesthetized animals. 
The treatment groups included mice receiving 1) liposomal DXR, 2) liposomal DXR + US, 3) 
saline (0.25 ml/animal), 4) saline (0.25 ml/animal) + US. 
Designated animals received US treatment at 24 h post-injection, when the tumour 
DXR concentration had reached peak levels. A 40 kHz ultrasonic transducer (Model VC 754, 
Sonic and Materials Inc., Newtown, CT, US) with a 19 mm diameter probe was partially 
submerged into a cylinder containing deionized and degassed water. The bottom of the cylinder 
was sealed with a latex membrane in firm contact with the skin covering the tumours located on 
an adjustable plate. A thin layer of US gel was placed between the skin and the latex membrane. 
The US probe was run at a nominal intensity of ~12 W/cm2 for a duration of 4 min and with a 2 
cm distance between the probe and skin. Preliminary tests were performed to ensure that the 
combination of probe-skin distance and duration of US exposure did not induce any visible 
local skin lesions. Tumour size was measured with 3-5 days intervals for 22 days using digital 
callipers (model B220S, Kroeplin, Schlüchtern, Germany). Tumour volume was calculated 
using the formula (!/6)*length2*width 49. Individual tumour volumes were normalized to pre-
treatment level on day 0. 
 
3.2.8 Statistical methods 
Multivariate data analysis (MVA) was performed with the software Unscrambler ! (version 
9.6, Camo Technologies Inc). Partial least square regression (PLS) analysis using full cross 
validation was used to analyse significance of lipid variables in the MVA at a probability level 
(p) <0.05. Prior to calculations the variation of each variable was scaled to unite variance (using 
1/SD as the scaling factor).  
For statistical comparison of two means, a student t-test was used at significant levels of 
p<0.05 or p<0.01. 
Differences in tumour growth delay between the four experimental groups in the 
therapy study were operationally represented by three between-group contrasts: 1) comparing 
the liposomal DXR groups and the saline groups, 2) comparing the US group with no-US within 
the liposomal DXR conditions and finally 3) comparing the US group with no-US within the 
saline conditions. The analysis was performed using normalised tumour volumes. The tumour 
growth delay was represented by developmental growth curves of linear and quadratic 
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polynomial contrasts, respectively, adjusted for unequal time intervals between the 
measurement points 50,51. 
 
4. RESULTS AND DISCUSSION 
 
4.1 Development of sonosensitive liposome membranes 
The influence of liposome membrane composition on in vitro sonosensitivity was investigated. 
Traditionally, PC-lipids are used as the major membrane component in liposomes for drug 
delivery. However, PC-based liposomes (Caelyx!, herein defined as standard liposomal DXR) 
comprising HSPC, DSPE-PEG 2000 and cholesterol showed low in vitro sonosensitivity, where 
only 9 ± 2% of the entrapped DXR was released after 6 min of 40 kHz US exposure in 
sucrose/HEPES solution (paper I, Figure 4.2).  
 In an attempt to enhance responsiveness of liposome membranes to acoustic energy, 
non-bilayer forming PEs having an inverted cone shaped geometry were included in traditional 
liposome bilayers composed of DSPC, DSPE-PEG 2000 and cholesterol. The hypothesis was 
that US energy could trigger membrane perturbations and/or lamellar to reverse hexagonal 
phase transitions, leading to drug release (Figure 4.1).  
 
Figure 4.1 Illustration of proposed mechanism for US-mediated drug release from liposomes 
containing non-bilayer forming lipids. US energy triggers lamellar to reverse hexagonal phase 
transitions in the liposome bilayer during US exposure, leading to drug release. Epitarget! 
 
4.1.2 DSPE-based liposomes 
Initially, DXR-containing liposomes comprising DSPE, DSPC, DSPE-PEG 2000 and 
cholesterol were prepared and investigated in terms of in vitro sonosensitivity (paper I). The 
long saturated acyl chains of DSPE were considered to provide stability to the membrane per se, 
whilst the slight tendency of the lipid to form HII phases was hypothesized to induce drug 
release upon US exposure.  
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Figure 4.2 shows increased liposomal drug release as a function of US exposure time. 
Inclusion of DSPE within the liposome bilayer resulted in a significantly enhanced 
sonosensitivity compared to traditional PC-based liposomes. For the particular formulations 
shown in Figure 4.2, liposomal DXR release after 6 min 40 kHz US showed a 7-fold increase 
by substituting DSPC with DSPE.  
 
Figure 4.2 US-mediated release profiles of DXR-containing liposomes consisting of the lipids; 
! DSPE, DSPE-PEG 2000 and cholesterol 62:8:30 mol %, " DSPC, DSPE-PEG 2000 and 
cholesterol 62:8:30 mol %, and #Standard liposomal DXR (HSPC:DSPE-PEG 
2000:cholesterol 57:5:38 mol %). (The Figure is reprinted from paper I). 
 
As proposed above, the positive effect of DSPE on sonosensitivty was suggested to be 
related to the inverted cone shaped geometry of the lipid which upon US exposure promotes 
induction of local defects or polymorphic phase transitions within micro-rafts in the liposome 
bilayer, leading to drug release. The long saturated acyl chains of DSPE occupy a large volume 
compared to the small polar headgroup, which makes the lipid undergo a L!-HII phase transition 
at temperatures above 80 °C and/or at high pressure 52,53. Pressure - and/or temperature jumps 
have previously shown to induce liposomal phase transitions 52-54. The sample temperature 
never exceeded 30 °C during the US experiments, excluding direct thermal effects on drug 
release (paper I). However, it is likely that extreme temperature and/or pressure jumps in the 
near vicinity of cavitating bubbles could induce drug release from liposomes. 
 
Influence of membrane composition on sonosensitivity of DSPE-based liposomes  
Alterations in membrane composition of DSPE-based liposomes were further investigated to 
elucidate the effects, interplay and optimum levels of the different membrane lipids on 
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sonosensitivity (paper I). A full factorial design was employed where liposomes comprising 
different molar ratios of DSPE, DSPE-PEG 2000, DSPC and cholesterol were prepared. The 
correlation between the membrane lipids and DXR release after 6 min 40 kHz US exposure was 
explored using PLS analysis. The design is outlined in Table 4.1.  
The actual mean intensity weight diameter of the formulations ranged from 83-90 nm, 
with P.I values less than 0.14, indicating narrow size distributions. Entrapment efficiencies of 
DXR were more than 92% for all formulations. The comparable mean sizes and loading 
efficiencies of the formulations should exclude potential influence of these factors in the MVA. 
 
Table 4.1 Levels of the lipids investigated in the full factorial design. All lipid levels are given 
in mol %. DSPC is used as a filler to obtain 100 mol %. (The Table is reprinted from paper I) 
Lipid variables  Level  
 -1 0 +1 
DSPE 47 54.5 62 
DSPE-PEG 2000 3 5.5 8 
Cholesterol 20 25 30 
 
Sonosensitivity of DSPE-based liposomes was dependent on membrane composition, 
where release after 6 min 40 kHz US varied from 15 to 69 % for the different formulations 
(paper I). DSPE had the strongest impact on the model, showing a positive correlation to 
sonosensitivity (Figure 4.3). For a fixed level of cholesterol (30 mol%) and DSPE-PEG 2000 (8 
mol%), an increase in DSPE content from 47 to 62 mol% increased the release extent with 51% 
after 6 min 40 kHz US (paper I).  
The slightly positive effect of DSPE-PEG 2000 on sonosensitivity was in agreement 
with previous studies on PC-based liposomes by Lin and Thomas 38,39. For the DSPE-based 
liposomes studied here, however, the effect of varying DSPE-PEG 2000 content (from 3-8 
mol%) on sonosensitivity was not significant. This indicated that above a certain level of 
PEGylation, no added benefit on sonosensitivity was achieved.  
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Figure 4.3 Regression coefficients (p<0.05) of the partial least square regression analysis 
describing the significance of lipids on US-mediated DXR release after 6 min 40 kHz US. The 
amplitude of the regression coefficients indicates the degree of their positive or negative impact 
on liposome sonosensitivity. (The Figure is reprinted from paper I). 
 
Furthermore, the observed interaction effect between DSPE and cholesterol implied an 
optimum in sonosensitivitiy at intermediate levels of cholesterol and high levels of DSPE 
(Figure 4.4). The model also showed a squared effect of cholesterol, implying a negative and 
nonlinear correlation between cholesterol level and sonosensitivity. In contrast, Lin and Thomas 
reported that the sonosensitivity of PC-based liposomes increased approximately proportionally 
with higher cholesterol concentrations 39. This indicates that the effect of cholesterol on 




Figure 4.4 Response surface plot of US-mediated liposomal DXR release as a function of DSPE 
and cholesterol levels (mol %). (6 min 40 kHz US data, DSPE-PEG 2000 level held constant at 
8 mol %). (The Figure is reprinted from paper I). 
 
4.1.3 DOPE-based liposomes 
The conditions for which PEs form HII phases can be modulated by changing the degree of 
unsaturation in the acyl chains, where increased unsaturation increases the tendency of the lipid 
to form HII structures 55. Hence, to further test the relevance of non-bilayer forming lipids on 
sonosensitivity, liposomes comprising the unsaturated analogue of DSPE (DOPE) was 
investigated (paper III). DOPE has a more pronounced inversed conical shape than DSPE, as 
given by a higher PP value. Under physiological conditions (pH 7.4) DOPE tends to form HII 
structures. Liposome bilayers can be formed, however, when DOPE is mixed with other 
stabilizing lipids such as PEGylated phospholipids 4,56.   
The DOPE-based liposomes showed a further improved sonosensitivity compared to 
DSPE-based liposomes (paper III). As shown in Figure 4.5, the DOPE-based liposome 
formulation displayed approximately 95% DXR release after 6 min 40 kHz US exposure vs. 
60% for the corresponding DSPE-based formulation. Both PE-based liposomes showed a 




Figure 4.5 DXR release profiles upon 40 kHz US exposure of ! DOPE-based liposomes 
(DOPE:DSPC:DSPE-PEG 2000:cholesterol; 62:10:8:20 mol%) in sucrose/HEPES solution.   
" DSPE-based liposomes (DSPE:DSPC:DSPE-PEG 2000:Cholesterol; 62:10:8:20 mol%) and 
# standard liposomal DXR (HSPC:DSPE-PEG 2000:Cholesterol; 57:5:38 mol%) are included 
for comparison. (The Figure is reprinted from paper III). 
 
Influence of membrane composition on sonosensitivity of DOPE-based liposomes  
A D-optimal mixture design was employed to systematically investigate the influence of the 
membrane lipids DOPE, DSPC, DSPE-PEG 2000 and cholesterol on sonosensitivity of DOPE-
based liposomes on exposure to high frequency US (1.13 MHz) (paper IV). The levels of the 
lipid variables are shown in Table 4.2. 1.13 MHz US might be regarded more clinically relevant 
than 40 kHz US due to improved focusing ability and reduced damage to intermediate healthy 
tissue.  
For practical reasons the liposomes in the study design contained calcein as a drug 
marker. Preliminary experiments showed no significant differences in sonosensitivity for 
DOPE-based liposomes comprising passively entrapped calcein or actively loaded DXR, 
respectively, indicating that sonosensitivity appeared to be attributable to membrane 
composition and not the type of entrapped drug or marker. The liposomes showed mean 
intensity weight liposome size diameters ranging from 81-89 nm, with P.I below 0.15, 
indicating narrow size distributions (paper IV).  
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Table 4.2 Overview of the lipid variables investigated.  
(The Table is reprinted from paper IV). 
Lipid variables Range (mol%) 
DOPE 52-72 
DSPC 5-20 
DSPE-PEG 2000 3-8 
Cholesterol 20-35 
 
Calcein release from liposomes increased with US (cavitation) dose (paper IV). All of 
the DOPE-based liposome formulations showed relatively high US-mediated release. Hence, 
the data used for multivariate modeling were generated at a low cavitation dose of 2000, which 
allowed for better detection in release variations for the different formulations. At this cavitation 
dose the extent of release varied from 30 to 64% depending on liposome membrane 
composition (paper III).  
PLS regression analysis confirmed a positive correlation of the non-bilayer forming 
lipids DOPE and DSPE-PEG 2000 to sonosensitivity, where increased levels of the lipids 
increased release (Figure 4.6). By contrast, cholesterol showed a pronounced negative effect on 













Figure 4.6 Regression coefficients (p<0.05) of the partial least square regression analysis of 
calcein release extent from liposomes at a cavitation dose of 2000 (1.13 MHz US). The 
amplitude of the regression coefficients indicates the degree of their positive or negative impact 
on liposome sonosensitivity. (The Figure is reprinted from paper IV). 
 
The negative correlation of cholesterol to sonosensitivity might be due to increased 
lipid packing of the bilayer, which might in turn reduce sonosensitivity for example by reducing 
the ability of DOPE to undergo local phase conversions upon US exposure. On the other hand, 
cholesterol has previously been reported to induce HII phase structure in mixtures of unsaturated 
PEs and bilayer-stabilizing phospholipids such as PCs 57.  
The observed interaction between DSPC and DOPE on sonosensitivity implies that for 
membranes containing low levels of DOPE, increased levels of DSPC reduced sonosensitivity. 
At higher levels of DOPE the DSPC content had no significant influence on sonosensitivity 
(Figure 4.7). The optimal membrane composition contained high levels of DOPE and DSPE-















Figure 4.7 Response surface plot showing the percentage US-mediated release of calcein from 
liposomes as a function of DOPE and DSPC content  (mol%) (1.13 MHz US, cavitation dose 
2000). DSPE-PEG 2000 and cholesterol levels are held constant at 8 and 20 mol%, 
respectively. The marked area is not included in the model. (The Figure is reprinted from paper 
IV). 
 
The chemometric studies of both DSPE- and DOPE-based liposomes indicate that the 
influence of lipid constituents on sonosensitivity are complex and may vary depending on the 
lipid mixture. Various underlying physicochemical properties such as lipid membrane packing, 
lipid miscibility and fluidity, depending on the lipid blend, are likely to influence on 
sonosensitivity. 
In a recent study by Cavalcanti et al., compressibility of DSPE- and DOPE-based lipid 
blends were evaluated by Brewster Angle Microscopy 58. An increased compressibility was 
reported for DOPE-lipid blends than DSPE-lipid blends, suggesting a correlation between 
compressibility of liposome membranes and sonosensitivity 58. However, the increased 
compressibility reported by increasing amounts of cholesterol in DSPE-based membranes did 
not fully support such a theory, as cholesterol in the current studies reduced sonosensitivity 
(Paper I). The polymorphic behavior of complex lipid blends and their effect on sonosensitivity 





4.1.4 DEPC-based liposomes  
Based on the strong effect of PEs in improving liposome sonosensitivity, liposomes comprising 
various lipids characterized by a cone shaped geometry were investigated in terms of 
sonosensitivity, including liposomes based on long unsaturated PCs like 
dierucoylphosphatidylcholine (DEPC). (For patent applications see 59-61). Increased acyl chain 
length and unsaturation is expected to increase the PP value and possible HII formation 3. An 
overview of the different formulations is given in appendix 1. There was a general trend that 
lipids with inverted cone shaped geometries (PP>1) increased sonosensitivity of liposomes. 
Micellar forming lipids (PP<1), like fatty acids, showed less influence on sonosensitivity. 
In the case of DEPC, the PC headgroup area is larger than that of PE, but the long 
unsaturated acyl chains (22:1 cis PC) increase the volume of the hydrophobic part of the 
molecule and hence the PP value. The liposome formulation DEPC:DSPC:DSPE-PEG 
2000:Cholesterol 52:5:8:35 mol% displayed high US-mediated DXR release profiles, where 74 
± 5% DXR (mean and SD of triplicate batches) was released after 6 min 40 kHz US in 
sucrose/HEPES solution. This represented a significant improvement in sonosensitivity 
comparing to DSPC-based liposomes (Paper I). The DEPC-based liposomes will not be further 
discussed in this thesis.  
 
4.2 High frequency US versus low frequency US 
HIFU might be considered more clinically relevant in tumour treatment than LFUS, due to 
improved focusing ability for tumours located deep in the body. Improved focusing implies 
minimal damage to surrounding healthy tissue. The different construction of the two US set-ups 
used in the current studies (40 kHz US and 1.13 MHz US) did not allow for a direct comparison 
between the liposome release data. However, the trends in sonosensitivity for the different 
liposomes investigated were similar irrespective of the US frequency used (Papers III and IV). 
Hence, for the purpose of sonosensitivity testing of liposomes in vitro both US set-ups were 
suitable. An advantage with the 40 kHz US set-up, however, was the possibility to perform 
release experiments in the presence of 20% serum. This was not feasible with the 1.13 MHz set-
up, as foaming and coagulations were produced during the US run which made it difficult for 
the hydrophone to detect cavitation.  
 
4.3 Sonosensitivity in serum-containing medium 
To provide a closer simulation of biological conditions, sonosensitivity studies were performed 
in 20% serum (papers III and V).  
The US-mediated drug release profiles (40 kHz US) in sucrose/HEPES solution 
containing 20% serum are shown in Figure 4.8. DSPE-based liposomes experienced a total loss 
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of sonosensitivity, whilst sonosensitivity of DOPE-based liposomes was essentially maintained 
(Paper III). It should be added that the loss of sonosensitivity in 20% serum was consistently 
seen for all of the DSPE-based liposome formulations investigated (data not shown). 
 
Figure 4.8 Release profiles of DXR on 40 kHz US exposure of ! DOPE-based liposomes 
(DOPE:DSPC:DSPE-PEG 2000:Cholesterol; 62:10:8:20 mol%) and " DSPE-based liposomes 
(DSPE:DSPC:DSPE-PEG 2000:Cholesterol; 62:10:8:20 mol%) in sucrose/HEPES solution 
containing 20% serum. # standard liposomal DXR (HSPC:DSPE-PEG 2000:Cholesterol; 
57:5:38 mol%) is included for comparison. (The Figure is reprinted from paper III).  
 
The reasons for the loss of sonosensitivity of DSPE-based liposomes in serum remain 
unclear. One explanation could be interactions between serum proteins and DSPE-based 
membranes, which affect the polymorphism or arrangement of the lipidbilayer and hence 
sonosensitivity. It has been shown previously that the structural preferences of lipids in a lipid 
blend can be modulated by factors such as proteins 57.  
Another factor that might influence on sonosensitivity is a reduction in the acoustic 
energy deposited to liposomes due to higher viscosity of the serum-containing medium. This 
could adversely affect release from DSPE-based liposomes whilst DOPE-based liposomes 
might be destabilized even at low acoustic energy. 
Figure 4.9 shows the amount of DOPE required in liposomes (comprising a fixed level 
of cholesterol and DSPE-PEG 2000 of 40 and 8 mol%, respectively), to maintain sufficient 
sonosensitivity in 20% serum. High sonosensitivity was observed for formulations comprising 
between 25 and 52 mol% DOPE (Figure 4.9). Poor sonosensitivity was observed for liposomes 
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with 12 mol% DOPE, as evidenced by a significant reduction in DXR release (Figure 4.9), 
(paper V).  
 
 
Figure 4.9 Effect of DOPE level on US-mediated DXR release from liposomes in 
HEPES/sucrose solution containing 20% serum (40 kHz US). DOPE-levels: ! 32 mol%, ! 52 
mol%, " 25 mol%, " 12 mol%. (Cholesterol and DSPE-PEG 2000 levels: 40 and 8 mol%, 
respectively. DSPC level co varies). (The Figure is reprinted from paper V). 
 
Higher serum concentrations would theoretically better simulate plasma. Unfortunately, 
it was not feasible to perform release experiments in higher serum concentrations than 20% as 
serum reduces the fluorescence signal of DXR. However, 20% serum should still give a good 
indication of the impact of serum components on liposome sonosensitivity. The high 
sonosensitivity of DOPE-based liposomes in 20% serum shows promise for US-mediated drug 
release in tumour tissue (See section 6 for qualitative US-mediated release studies in vivo). 
 
4.4 Mechanisms of US-mediated drug release  
The mechanisms of US-mediated permeabilization of phospholipid membranes and drug release 
from liposomes have not been clearly elucidated in literature. To investigate the mechanism of 
US-mediated drug release of DOPE-based liposomes, liposome size and morphology were 
studied before and after 40 kHz US exposure by PCS and Cryo-TEM  (paper III). The non-
exposed samples showed mainly small unilamellar vesicles, slightly below 100 nm in diameter, 
with rod-like structures spanning the aqueous core indicating DXR precipitate (paper III). The 
US-treated liposomes displayed a significant change towards a broader size distribution, as 
shown by an increased P.I. A mixture of smaller and larger empty vesicles as well as non-
! "#!
lamellar structures was observed (paper III). The results indicate US-induced destabilization and 
disruption of DOPE-based liposomes, explaining the high drug release. Similar results were 
observed for US-treated DSPE-based liposomes (data not shown). 
 It was of further interest to investigate whether US-mediated disruption of vesicles was 
a release mechanism that was specific for PE-based liposomes. Hence, the size and morphology 
of PC-based liposomes (standard liposomal DXR) was examined before and after US treatment 
with Cryo-TEM and PCS. To allow for a relative comparison between DOPE-based liposomes 
and standard liposomal DXR the formulations were investigated for a given release extent. 
However, when exposing low-diluted standard liposomal DXR to 12 min US, using the 40 kHz 
US set-up, less than 5% of the entrapped DXR was released from liposomes. To obtain 
sufficient drug release the US transducer had to be immersed directly into the liposome 
dispersions diluted in a 1/10 (v/v) ratio with 0.22 µm-filtered sucrose/HEPES solution. A water 
bath was used to keep the temperature below 30°C. This powerful US treatment resulted in 
approximately 60% DXR release from both DOPE-based liposomes and standard liposomal 
DXR after 2 and 6 min of US exposure, respectively.  
The structure of untreated DOPE-based liposomes and standard liposomal DXR was 
approximately similar (Figure 4.10 A, C). The liposome membranes are shown as the darker 
perimeters surrounding the inner aqueous compartment with precipitated DXR. After US 
treatment standard liposomal DXR showed, in contrast to the DOPE-based liposomes, no 
significant changes in liposomes size distribution or liposome structure (Table 4.3, Figure 4.10 
B, D). The electron micrographs revealed mainly intact and empty vesicles, the latter 
confirming DXR release.  In addition a few rod-like structures were seen, indicating DXR 
and/or cholesterol crystals (Figure 4.10 B). The results were in agreement with previous 
findings by Schroeder et al., showing no significant changes in size or structure of PC-based 
liposomes exposed to low frequency US 62. 
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Table 4.3  Mean size (intensity weighted) and P.I of standard liposomal DXR and DOPE-based 
liposomes before and after 40 kHz US exposure. DXR release for both liposome formulations is 
60%. 
Mean size, nm P.I Liposome 
formulation Untreated sample US-treated sample Untreated sample US-treated sample 
DOPE-liposomes 86 ± 2 90 ± 3 * 
 
0.14 ± 0.03 0.25 ± 0.01 
Standard 
liposomal DXR 
74 ± 1 76 ± 1 0.10 ± 0.01 0.11 ± 0.01 














Figure 4.10 Cryo-TEM micrographs showing lipid structures before and after US treatment of 
A) Non-treated standard liposomal DXR (HSPC:DSPE-PEG 2000:Cholesterol 57:5:38 mol%), 
B) US-treated standard liposomal DXR, C) Non-treated DOPE-based liposomes 
(DOPE:DSPC:DSPE-PEG 2000:Cholesterol; 62:10:8:20 mol%), D) US-treated DOPE-based 
liposomes. Both of the US treated liposome formulations have released approximately 60% of 
the entrapped DXR. The micrographs shown are representative for the whole specimen. Note 
that the US treated liposomes are diluted 1:10 v/v with sucrose/HEPES solution. 
 
The type of lipid structures formed in the US-treated DOPE-based liposome sample was 
difficult to identify from the micrographs. A large fraction of smaller structures was observed 
(Figure 4.10 D) indicating small vesicles or micelles. Due to the heterogeneous size distribution 
of the sample, the smaller structures were most likely underestimated in the calculation of mean 
particle size by PCS, which is a general limitation of the method 63.  
The results indicated different release mechanisms for standard liposomal DXR and 
DOPE-based liposomes. This in turn might explain the large difference in sonosensitivity for 
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the two formulations. Previous reports have suggested that US-sensitization of PC-based 
liposomes induces reversible pore-like defects in the membrane allowing drug release 38,62. The 
fact that the standard liposomal DXR investigated here remained mainly as intact empty 
vesicles after US release supports such a theory.  
As already suggested, the US-mediated disruption of DOPE-based liposomes might be 
related to membrane phase conversions as DOPE adapts to a HII phase upon exposure to 
acoustic energy. PEGylated phospholipids stabilize DOPE into a lamellar phase 4,56. Hence, 
potential US-induced shedding of DSPE-PEG 2000 from the liposomes might destabilize the 
DOPE-containing bilayer due to phase conversions. US or pressure-driven exchange of 
PEGylated lipids with the external aqueous phase is possible as PEG-lipids have significantly 
greater water solubility than their parent lipids 64. 
It should be added that 31P nuclear magnetic resonance has been attempted to identify 
the type of lipid structures formed after US treatment of the DOPE-based liposomes, e.g. 
presence of potential HII structures. Unfortunately, the results were inconclusive as isotropic 
phases made it difficult to distinguish and identify the different structures. Small angle X-ray 
scattering could be an alternative approach. However, potentially reversible and 
thermodynamically unstable lipid structures formed during US treatment may complicate the 
data interpretation. Simplified liposome models without DXR composed of for example only 
DOPE and DSPE-PEG 2000 could be used to reduce the complexity of the structures formed 
post US.  
 
4.5 Chemical integrity of US treated doxorubicin and lipids   
Chemical integrity of DXR-containing DOPE and DSPE-based liposomes before and after 
exposure to 40 kHz US and 1 MHz US, respectively, was analyzed by HPLC. The studies were 
performed to investigate whether potential sonochemical effects induced degradation of the 
lipids and/or DXR. The tested DOPE-based liposomes contained DOPE:DSPC:DSPE-PEG 
2000:Cholesterol in molar ratios of 62:10:8:20 mol%. The tested DSPE-based liposomes 
contained DSPE:DSPE-PEG 2000:Cholesterol in molar ratios of 62:8:30 mol%.  
 The assays of DXR, cholesterol and phospholipids, respectively, were identical before 
and after US, indicating that the US treatments used did not degrade the molecules. No 
impurities/degradation products of DXR were detected. The results were in agreement with 
previous findings by Schroeder et al., showing that LFUS do not affect the chemical integrity of 
DXR and lipids nor the biological potency of released DXR62. 
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4.6 Storage stability  
The storage stability of a liposomal drug formulation is an important pharmaceutical concern. 
Liposome storage stability includes colloid stability, drug retention and chemical integrity of 
both drug and lipids. For the sonosensitive liposomes it is important that these physicochemical 
properties are preserved at least from the time of production to time of application. 
Hence, stability of selected DXR-containing DOPE and DSPE-based liposome 
formulations, considered as promising product candidates based on sonosensitivity and in vitro 
serum stability tests, was followed during 6 months storage at 5 °C. The tested DOPE-based 
liposomes contained DOPE:DSPC:DSPE-PEG 2000:Cholesterol in molar ratios of 62:10:8:20 
mol% and 25:27:8:40 mol%. The tested DSPE-based liposomes contained DSPE:DSPC:DSPE-
PEG 2000:Cholesterol in molar ratios of 62:0:8:30 mol% and 54.5:10:5.5:30 mol%.  
The data showed no detectable leakage of liposomal DXR, no significant alteration in 
sonosensitivity, mean liposome size, P.I nor assay of phospholipids and DXR, during storage.  
The high drug retention of the liposomes upon storage might be explained by the 
presence of cholesterol that reduces permeabilization of the liposome membrane and 
consequently drug leakage8. Furthermore, the small size of the liposomes and the PEGylated 
surface is expected to minimize or prevent liposome aggregation and/or fusion8.  
 
4.7 Serum stability  
In vitro serum assays are often performed prior to in vivo studies to investigate liposome 
stability in terms of drug retention under simulated biological conditions. Serum stability 
strongly depends on liposome membrane composition and is induced by interactions between 
membrane phospholipids and serum proteins, such as albumin and lipoproteins 8,65.  
Drug leakage from DSPE and DOPE-based liposomes was determined after 6 h 
incubation in sucrose/HEPES solution containing 20% serum at 37 °C (Papers I, II, III, IV, V). 
The DSPE-based liposomes, included in the full factorial design described in Table 4.1, showed 
variations in DXR leakage from 2 to 37%, depending on membrane composition (Paper I). PLS 
regression analysis examining the influence of the membrane lipids DSPE, DSPE-PEG 2000 
and cholesterol on serum stability, revealed a major influence of cholesterol. At a constant level 
of DSPE and DSPE-PEG 2000 (47 and 3 mol%, respectively) a reduction in liposomal DXR 
leakage from 28 to 6% was obtained by increasing the cholesterol level from 20 to 30 mol% 
(paper I). The stabilizing effect of cholesterol might be explained by its known ability to tighten 
liposome membranes, reduce the extent of opsonisation and minimize loss of encapsulated drug 
6.  
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Also DSPE-PEG 2000 had an influence on serum stability of DSPE-based liposomes. 
In general, PEGylation of liposomes is known to sterically prevent or minimize interactions 
between the liposome membrane and serum proteins, thus improving liposome stability. The 
squared effect observed for the DSPE-based liposome formulations implied a negative, but non-
linear correlation of DSPE-PEG 2000 content on serum-induced drug leakage (Figure 4.11).  
 
 
Figure 4.11 Regression coefficients describing the significance of lipids on DXR leakage extent 
(%) from DSPE-based liposomes after 6 h incubation in 20% serum/ 37 °C. (The Figure is 
reprinted from paper I). 
 
The DOPE-based liposomes showed no detectable leakage of DXR nor calcein in 
serum, irrespective of membrane composition (Papers III,IV,V). Hence, the DOPE-based 
liposomes were stable in 20% serum compared to most of the DSPE-based liposome 
formulations (paper I). These data are contradictory to the general conception that liposome 
membranes comprising unsaturated lipids are more permeable and prone to drug leakage than 
liposomes composed of saturated lipids 66,67. However, DSPE-based liposomes incubated in 
sucrose/HEPES solution without serum showed no DXR leakage, indicating that the leakage 
observed for DSPE-based liposomes in 20% serum was a result of serum components and not 
passive leakage (paper I).  
The serum-induced leakage for selected DSPE-based formulations might be explained 
by poor lipid membrane packing or structural defects in the bilayer that causes penetration by 
proteins. The surface of small-sized liposomes below Tc often appears rigid and polyhedron-
like, which makes the membrane more prone to opsonisation 28. For liposomes in the liquid 
crystalline phase (above Tc), the membrane surface is typically smooth and curved, minimizing 
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interactions with proteins 28. DSPE display a significantly higher Tc (74 °C) than DOPE (-16 
°C) and should hence provide a more rigid bilayer at physiological temperatures. This can 
clearly be observed in Figure 4.12, where CryoTEM of DSPE- and DOPE-based liposomes are 
shown. The fluid DOPE-based liposome membranes appear smooth and curved, whilst the rigid 
DSPE-based liposomes are polyhedron-like. Inclusion of cholesterol (above 30 mol%) in 
liposomes has previously shown to give rise to a liquid ordered phase 28, which could explain 
the improved serum stability for DSPE-based liposomes with higher cholesterol levels. 
 
A  B  
Figure 4.12 CryoTEM of DXR-containing liposomes; A) DSPE-based liposomes 
(DSPE:DSPC:DSPE-PEG 2000:Cholesterol; 62:10:8:20 mol%) and B) DXR-containing 
DOPE-based liposomes (DOPE:DSPC:DSPE-PEG 2000:Cholesterol; 62:10:8:20 mol%). The 
micrographs shown are representative for the whole specimen. 
 
It should be emphasized that in vitro serum stability assays are not always indicative of 
in vivo stability in terms of liposomal drug leakage in blood circulation28,8,67. Hence, the most 
relevant studies of liposome stability are performed in vivo.  
 
4.8 Pharmacokinetic studies  
There is a well-established correlation between long blood circulation time and increased 
accumulation of liposomes in tumours 68. Several biodistribution studies performed in tumour-
bearing mice with PEGylated DXR-liposomes describe a peak DXR tumour concentration 1-2 
days post injection 18,69,70. Hence, for efficient US-mediated drug delivery to solid tumours, 
liposomes must retain their drug load while in circulation.  
Blood pharmacokinetics of selected liposome formulations that combined both high in 
vitro sonosensitivity and serum stability was evaluated in non-tumoured mice (paper V). As 
only the blood pharmacokinetics were evaluated, it was found more practical to use healthy 
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mice instead of tumour-bearing mice in the study. Figure 4.13 shows the blood clearance 
profiles of the optimized DSPE-based liposome formulation in comparison to DOPE-rich 
liposomes and standard liposomal DXR. Despite good serum stability in vitro, the DOPE-rich 
liposomes (52-62 mol% DOPE) displayed a significantly faster DXR blood clearance in 
comparison to standard liposomal DXR and optimized DSPE-based liposomes (Figure 4.13) 
(paper V). At 24 h post-injection only 5% of the injected DXR dose for DOPE-based liposomes 
remained in blood, vs. 20% for standard liposomal DXR (Figure 4.13).  
 
Figure 4.13 Blood clearance of liposomal DXR in healthy mice. ! DOPE-based liposomes 
(DOPE:DSPC:DSPE-PEG 2000 2000:Cholesterol; 62:10:8:20 mol%), ! DSPE-based 
liposomes (DSPE:DSPE-PEG 2000:Cholesterol 62:8:30 mol%) and ! standard liposomal DXR 
(HSPC:DSPE-PEG 2000:Cholesterol; 57:5:38 mol%).  
 
The relatively faster blood clearance of DOPE-rich liposomes might reflect leakage of 
DXR from the liposome carrier and/or premature uptake of the liposomes by the MPS. Previous 
studies have demonstrated faster blood clearance kinetics of liposomal drugs composed of 
unsaturated lipids like DOPE, due to high membrane permeability and drug leakage from the 
liposome carrier 66,71,72.  
In an attempt to prolong blood circulation time of DOPE-containing liposomal DXR, 
the membrane composition was altered by both increasing the level of cholesterol and reducing 
the level of DOPE. Cholesterol has been shown to tighten liposome membranes, minimize 
opsonisation and decrease leakage of entrapped material 6,47,72,73. 
An overview of the different liposome formulations prepared is presented in Table 4.4. 
All liposomes displayed DXR encapsulation efficiencies above 95%. Due to the general 
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influence of liposome size on pharmacokinetics8, the comparable size of the formulations (Table 
4.4) was essential to better assess the influence of the membrane composition per se on blood 
pharmacokinetics. 
Table 4.4 Overview of the different DOPE-containing liposome formulations evaluated in 
pharmacokinetic studies in mice. (The Table is reprinted from paper V) 
 
Increasing the cholesterol level from 20 to 40 mol% in DOPE-rich liposomes did not 
result in prolonged blood circulation time of DXR. The lack of a cholesterol stabilizing effect 
might be related to lipid packing constraints such as inhomogeneous distribution of cholesterol 
within the lipid membranes and/or poor cholesterol-phospholipid interactions, leading to high 
membrane permeability 5.  
A significantly longer blood circulation time of DXR was obtained for liposomes with 
reduced levels of DOPE (32 and 25 mol%) (Figure 4.14). As the DOPE amount was reduced, 
DSPC was consequently increased (Table 4.4). Hence, the reduced blood clearance was most 
likely a result of both an increased DSPC level and reduced DOPE level. Previous studies have 
shown that saturated PCs impart order and rigidity to liposome membranes, increases the 
overall Tc and prolongs the blood residence time of liposomal drugs due to reduced liposomal 
drug leakage 5,66,74,72. 
Biodistribution studies showed no increase in DXR uptake in liver, spleen and kidneys 
for DOPE-rich liposomes, which displayed the fastest blood clearance (paper V). Hence, the 
reduced blood clearance of DXR for intermediatelevel DOPE-containing liposomes was 
suggested to be due to less drug leakage from the liposomes in blood circulation and not 
reduced uptake by the MPS (paper V). Furthermore, DXR blood levels provide a good 
indication of liposome encapsulated drug, since DXR released in the bloodstream is rapidly 




Mean size, nm 
(P.I) 
% DXR in blood circulation 
24 h post i.v. injection.  
62:10:8.20 
86 (0.14) 5 ±  1 
52:5:8:35 86 (0.12) 3 ± 1 
52:20:8:20 80 (0.10) 4  ± 1 
52:0:8:40 86 (0.10) 2 ± 0 
32:20:8.40 86 (0.10) 20 ± 3 
25:27:8:40 87 (0.10) 17 ± 1 
Standard liposomal DXR 76 (0.11) 21 ± 1 
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Figure 4.14 Blood clearance kinetics of liposomal DXR in mice for liposomes containing the 
following DOPE levels; ! 25 mol% and "32 mol%. (Cholesterol and DSPE-PEG 2000 levels: 
40 and 8 mol%, respectively. DSPC levels co varies with DOPE). # standard liposomal DXR 
(HSPC:DSPE-PEG 2000:Cholesterol; 57:5:38 mol%) is included for comparison. (The Figure 
is reprinted from paper V). 
 
The liposomes containing 25-32 mol% DOPE, 8 mol% DSPE-PEG 2000 and 40 mol% 
cholesterol, showed approximately similar blood pharmacokinetics as standard liposomal DXR, 
where 20% of the injected DXR dose remained in blood circulation at 24 h post-injection 
(Figure 4.14). Furthermore, the reduction in DOPE content did not adversely reduce 
sonosensitivity (paper V). Considering both the blood clearance and sonosensitivity data in 20% 
serum, liposomes containing intermediate DOPE levels were the optimal formulations 
identified.  
 
4.9 In vivo proof of principle study with prototype sonosensitive liposomes 
Tumour regression was studied in mice bearing CWR22 prostate adenocarcinoma treated with 
prototype DSPE-based DXR-containing liposomes and 40 kHz US (paper II). The aim was to 
investigate whether an improved therapeutic effect could be obtained by combining 
sonosensitive liposomes and US. The liposome formulation used, however, (composed of 
DSPE:DSPC:DSPE-PEG 2000:Cholesterol 54.5:10:5.5:30 mol%) is regarded as a prototype 
formulation as it displayed lower in vitro sonosensitivity comparing to other formulations 
developed in later formulation work. 
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Tumours were exposed to 4 min 40 kHz US at 24 h post i.v. injection of 3.5 mg/kg 
liposomal DXR, coinciding with the peak DXR tumour concentration (paper II). Mice treated 
with liposomal DXR without US, saline, and saline + US, respectively served as controls. 
 Figure 4.15 shows the tumour growth curves of the different treatment groups vs. time. 
No difference between groups receiving saline and saline + US was observed, indicating that 
US alone did not inhibit tumour growth. Furthermore, no difference was found between 
liposomal DXR groups and the saline control groups. However, the groups representing 
liposomal DXR and US showed a significant slower tumour growth trend compared to the 
control groups (p<0.05). 
 
Figure 4.15 Tumour growth evolution in mice receiving different treatments. The injected 
liposomal DXR dose was 3.5 mg/kg. (The Figure is reprinted from paper II). 
 
The fact that no anti-tumour effect was obtained with the group receiving liposomal 
DXR indicates a lack of tumouricidic concentrations of released DXR in tumours. The rationale 
for using a relatively low DXR dose of 3.5 mg/kg was to avoid therapy saturation levels where 
any beneficial effects induced by US would not be measureable. Only 10% of the injected DXR 
dose remained in the blood at the time of US treatment (24 h post-injection), implying a minor 
contribution of liposomal DXR in the tumour vasculature (paper II). Furthermore, if DXR were 
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retained within liposomes when entering the tumour tisssue, the bioavailability of DXR to 
tumour cells might be limited. The US-enhanced tumour regression response supports such a 
theory.  
The tumour regression effect of combining US and liposomal drug is in consistency 
with previous studies 75,76. The anti-tumour effect obtained at a low DXR dose indicates that this 
system may benefit in cases where low DXR doses are required due to toxicity problems. 
However, the formulation used in the current study was suboptimal in terms of sonosensitivity 
in 20% serum comparing to optimized DOPE-liposome formulations developed later on during 
formulation work (paper V). Hence, other factors than US-mediated drug release might explain 
the US-enhanced antitumour growth, such as US-induced tumour extravasation of liposomes 
and/or improved drug cellpermeability.  
The mice were monitored throughout the therapy study for acute toxicity in terms of 
weight loss (paper II). All experimental groups experienced an initial weight loss independent 
of treatment, mainly due to the administration of anaesthesia. The maximum weight reduction 
was less than 10% for the group receiving liposomal DXR and US, which was considered 
acceptable (Figure 4.16). Previous toxicity studies with PEGylated liposomal DXR in mice have 
reported LD10 and LD50 to be 11.7 and 38.3 mg DXR/kg, respectively 77.  The US treatment 





Figure 4.16 Normalised body weight time evolution of mice receiving different treatments. The 
injected liposomal DXR dose was 3.5 mg/kg. (The Figure is reprinted from paper II).  
 
Peak levels of DXR in spleen and liver at 24 h post-injection represented 8 and 35% of 
the injected dose, respectively (paper II). Compared to other studies with standard liposomal 
DXR18 and DOPE-containing liposomes (paper V), these higher concentrations indicate 
increased DXR uptake by the MPS for DSPE-based liposomes. Hence, liposome uptake or 
accumulation in organs such as liver, spleen and skin might account for the slightly higher 
weight loss of the group receiving liposomal DXR.  
The therapy results indicate proof of principle and are promising for further 
development and improvement of the technology. Therapy studies with optimized DOPE-
containing liposomes at clinically relevant doses in combination with optimized US treatment 
(confocal high frequency US, 1.13 MHz) are ongoing to investigate whether the therapeutic 





Inclusion of the non-bilayer forming lipids DSPE and DOPE, respectively, in traditional 
liposome membranes containing DSPC, DSPE-PEG 2000 and cholesterol, significantly 
enhanced in vitro sonosensitivity. Variations in lipidbilayer composition influenced on 
sonosensitivity of both DSPE- and DOPE-based liposomes. DOPE, defined by a more 
pronounced inverted cone shaped structure than DSPE, was the most potent lipid modulator of 
sonosensitivity where only limited amounts (25 mol%) were required to obtain sufficient 
sonosensitivity. US release experiments in the presence of serum showed reduced 
sonosensitivity of DSPE-based liposomes, whilst sonosensitivity of DOPE-based liposomes was 
essentially maintained. 
CryoTEM and PCS studies indicate different US-mediated release mechanisms for 
DOPE-based liposomes vs. traditional PC-based liposomes (standard liposomal DXR). Standard 
liposomal DXR remained mainly as intact, empty vesicles after US treatment, indicating US-
induced pore-formation in the liposome membrane as the main cause of drug release. In 
contrast, the DOPE-based liposomes were mostly irreversibly disrupted after US treatment.  
DOPE-containing liposomes showed generally improved stability in 20% serum in 
terms of drug retention compared to DSPE-based liposomes. Despite acceptable stability in 
vitro, DOPE-rich liposomes (52-62 mol% DOPE) displayed a relatively fast blood clearance 
compared to both DSPE-based liposomes and standard liposomal DXR. However, by reducing 
the DOPE level in liposomes to 25-32 mol%, a prolonged blood circulation time was obtained. 
The optimized DOPE-containing liposomes, comprising 32 mol% DOPE, 20 mol% DSPC, 8 
mol% DSPE-PEG 2000 and 40 mol% cholesterol, showed similar blood clearance profile as 
standard liposomal DXR but a 8-fold improvement in vitro sonosensitivity in 20% serum. The 
DOPE-containing liposomes were the most promising product candidates as they fulfilled all 
the formulation criteria, including high sonosensitivity in 20% serum and long blood circulation 
time in mice. 
An enhanced tumour regression of combining low frequency US and prototype DSPE-
based liposomal DXR was demonstrated in tumoured mice. The data supports the concept that 
US mediated drug release provides a clinical benefit. Further optimization studies remain to 
investigate whether the DOPE-containing liposomes in combination with US treatment may 
further improve the therapeutic index of DXR.  
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6. GENERAL REMARKS AND FUTURE PERSPECTIVES 
 
Studies are ongoing to further evaluate the novel sonosensitive DOPE-containing liposomes in 
several in vivo animal models. A brief note of the ongoing studies and future perspectives is 
given in this section. 
 
Visualizing US-mediated release from liposomes in vivo by optical imaging.  
To investigate US-mediated release in vivo liposomes containing the fluorescent porfyrin 
Phthalocyanine chloride tetrasulfonic acid (AlS4) were prepared. AlS4 has an excitation 
wavelength in the near infrared region and can therefore be detected in vivo by optical imaging 
78. Encapsulation of AlS4 into liposomes leads to quenching and signal loss, which is recovered 
when the AlS4 is released from the liposome.  
  AlS4-containing DOPE-liposomes (DOPE:DSPC:DSPE-PEG 2000:Cholesterol 
25:27:8:40 mol%) and AlS4-containing HSPC-liposomes (HSPC:DSPE-PEG 2000:Cholesterol 
57:5:38 mol%) (mean liposome size diameters of 98 ± 1 nm and 101±3 nm, respectively), were 
prepared by the thin-film hydration and sequential extrusion technique as previously described. 
AlS4 was passively entrapped in the liposomes by hydration of the dry lipid films with an 
isotonic PBS solution containing 5 mM AlS4 (pH 7).  
100 µl of the AlS4-containing liposomes were directly injected into tumourvasculature 
of 22RV1 tumour-bearing athymic male nude mice. Whole body images of the mice were taken 
before and after exposing tumours to 1 min of 1.13 MHz US, using a confocal US set-up 
developed at INSERM, Lyon, France. The cavitation zone was positioned between the skin 
surface and the centre of the tumour.  
As seen in Figure 6.1 AlS4-containing DOPE-liposomes showed considerable US-
mediated release of AlS4 in tumours as evidenced by a significant increase in fluorescence 
signal intensity of factor 2.1 ± 0.7 (p<0.05, n=4). No significant increased fluorescence intensity 
in tumours injected with AlS4-containing HSPC-liposomes was observed after US treatment 
(n=4) (Figure 6.2). The results were consistently seen in all mice although there was a large 
variation between animals. Negative control animals, receiving no US, showed no increased 
fluorescence intensity, indicating that release was a result of US and not other factors such as 
passive leakage of AlS4 or destabilization of the liposomes due to for example tumour-
associated macrophages. The results indicate that the DOPE-liposomes maintained 
sonosensitivity also in vivo. 
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A  B  
Figure 6.1 Mice receiving intratumoural injection of AlS4-containing DOPE-liposomes A) 
before US treatment and B) after US treatment. The mouse to the left in both images is an 
untreated control. 
C  D  
Figure 6.2 Mice receiving intratumoural injection of AlS4-containing HSPC-liposomes C) 
before US treatment and D) after US treatment. The mouse to the left in both images is an 
untreated control. 
 
The variation in data between the different mice indicated large tumour biological 
differences such as vascularisation and/or tumour permeability as well as presence of necrotic 
tissue. These factors may both affect tumour distribution of the liposomes as well as the extent 
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of cavitation produced in the tumour tissue. Improved monitoring of US dosimetry should be 
accomplished to better control the cavitation produced in different tumours. 
It should be added that i.v. administration of the AlS4-containing DOPE-liposomes 
followed by US exposure of tumours at 5 and 24 h post-injection, respectively, did not increase 
the fluorescence intensity. Whether this was due to premature leakage of liposomal AlS4 prior 
to or upon accumulation in the tumour, poor assay sensitivity for low concentrations of AlS4 in 
the tumour tissue, lack of US-mediated release or other factors needs further investigation. 
 
Therapy studies in tumoured rats 
Tumour regression studies in rats receiving DXR-containing DOPE-liposomes and high 
frequency US are ongoing to further confirm the concept of US mediated drug release. Higher 
US frequencies (500 kHz-1.13 MHz) would give a more focused US beam, localizing cavitation 
only in the tumour tissue. Preliminary toxicology of both liposomes and US treatments and the 
combination of these are currently being investigated.  
 
Loading of cytotoxic drugs in sonosensitive liposomes 
Other relevant chemotherapeutic drugs than DXR as well as genetic material such as siRNA is 
under consideration for loading in DOPE-containing liposomes for improved targeted delivery 
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Begrensingen med dagens kjemoterapi er uspesifikk distribusjon av cellegift i kroppen, noe som 
gir systemiske bivirkninger og redusert effekt. En ny strategi for å øke målstyring av cellegift til 
tumorer og kreftceller er å kombinere ultralydresponsive (sonosensitive) cellegift-bærende 
liposomer med ultralyd. Liposomer er nanovesikler som kan frakte cellegift til tumor via 
blodbanen. Ved å applisere ultralyd direkte mot tumor vil en kunne oppnå selektiv frigivelse av 
cellegiften fra liposomene samt øke opptak i kreftcellene. Dette forutsetter imidlertid at 
liposomene er sonosensitive, dvs. liposomene gir tilstrekkelig frisetting av cellegiften ved 
eksponering av ultralyd.   
I denne studien har vi utviklet nye sonosensitive liposomer som inneholder cellegiften 
doxorubicin. Resultatene har gitt innsikt i hvilke membranparametere som innvirker på 
sonosensitivitet av liposomer. Liposomer basert på såkalte ikke-lamellære lipider (som lipidet 
DOPE) viste en signifikant forbedret sonosensitivitet sammenlignet med tradisjonelle 
liposomer, Caelyx!. Mekanismen bak frisetting av doxorubicin fra DOPE-baserte liposomer så 
ut til å være irreversibel ødeleggelse av liposom membranen under ultralydbehandling. Denne 
mekanismen så ikke ut for å være gjeldende for tradisjonelle liposomer.  
Liposomer med både høy sonosensitivitet og lang sirkuleringstid i blodbanen ble 
utviklet ved å optimalisere membrankomposisjonen. Lang sirkuleringstid i blod er ønskelig for 
å oppnå mest mulig akkumulering av liposomene i tumorvev. Ved å kombinere prototype 
sonosensitive liposomer og ultralyd i tumor-bærende mus viste vi en signifikant redusert tumor 
vekst sammenlignet med kontroll grupper (mus som enten fikk liposomer eller ultralyd). 
Resultatene er lovende for videre utprøvning av sonosensitive liposomer for ultralydmediert 




Liposome membrane composition Non-bilayer 
lipid 
EE % Mean 
size, nm 
(P.I) 
% US-mediated release in 
buffered sucrose (40 kHz US)* 
X:DSPC:DSPE-PEG 2000:cholesterol X   2 min 4 min 6 min 
 
62:10:8:20 DOPE 94 86 (0.14) 69±3 87±2 95±2 
62:10:8:20 SOPE 97 86 (0.06) 24±3 48±6 70±6 
62:10:8:20 DSPE 99 85 (0.08) 46±3 59±3 64±3 
62:10:8:20 DPPE 98 88 (0.07) 9±2 14±2 18±3 
52:5:8:35 DNPC 93 82 (0.08) 55±4 78±4 87±4 
52:5:8:35 DEPC 97 87 (0.10) 44±2 67±3 76±3 
25:27:8:40 DOPC 95 88 (0.07) 22±2 36±4 45±4 
25:27:8:40 Oleic acid 96 84 (0.14) 20±2 30±2 35±1 
25:27:8:40 Stearic acid 96 86 (0.07) 4±1 14±1 25±1 
25:27:8:40 Lyso PC 100 88 (0.07) 7±1 13±3 18±3 
*The mean of triplicate US measurements of one liposome batch is given. 
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